Akbaş Türkay, Güneş Harun
Division of Intensive Care, Department of Internal Medicine, School of Medicine, Düzce University, Düzce, Türkiye.
Department of Emergency Medicine, School of Medicine, Balıkesir University, Balıkesir, Türkiye.
Acute Crit Care. 2023 Feb;38(1):49-56. doi: 10.4266/acc.2022.01011. Epub 2023 Feb 27.
The study aimed to describe the clinical course, outcomes, and prognostic factors of chronic obstructive pulmonary disease (COPD) patients with acute hypercapnic respiratory failure.
This retrospective study involved patients with acute hypercapnic respiratory failure due to COPD of any cause admitted to the intensive care unit (ICU) for non-invasive or invasive mechanical ventilation (IMV) support between December 2015 and February 2020.
One hundred patients were evaluated. The main causes of acute hypercapnic respiratory failure were bronchitis, pneumonia, and heart failure. The patients' mean Acute Physiology and Chronic Health Evaluation (APACHE) II score was 23.0±7.2, and their IMV rate was 43%. ICU, in-hospital, and 90-day mortality rates were 21%, 29%, and 39%, respectively. Non-survivors had more pneumonia, shock within the first 24 hours of admission, IMV, vasopressor use, and renal replacement therapy, along with higher APACHE II scores, lower admission albumin levels and PaO2/ FiO2 ratios, and longer ICU and hospital stays than survivors. Logistic regression analysis identified APACHE II score (odds ratio [OR], 1.157; 95% confidence interval [CI], 1.017-1.317; P=0.026), admission PaO2/FiO2 ratio (OR, 0.989; 95% CI, 0.978-0.999; P=0.046), and vasopressor use (OR, 8.827; 95% CI, 1.650-47.215; P=0.011) as predictors of ICU mortality. APACHE II score (OR, 1.099; 95% CI, 1.021-1.182; P=0.011) and admission albumin level (OR, 0.169; 95% CI, 0.056-0.514; P=0.002) emerged as predictors of 90-day mortality.
APACHE II scores, the PaO2/FiO2 ratio, vasopressor use, and albumin levels are significant short-term mortality predictors in severely ill COPD patients with acute hypercapnic respiratory failure.
本研究旨在描述慢性阻塞性肺疾病(COPD)合并急性高碳酸血症呼吸衰竭患者的临床病程、结局及预后因素。
本回顾性研究纳入了2015年12月至2020年2月期间因任何原因导致急性高碳酸血症呼吸衰竭而入住重症监护病房(ICU)接受无创或有创机械通气(IMV)支持的COPD患者。
共评估了100例患者。急性高碳酸血症呼吸衰竭的主要病因是支气管炎、肺炎和心力衰竭。患者的急性生理与慢性健康状况评估(APACHE)II评分均值为23.0±7.2,IMV使用率为43%。ICU死亡率、住院死亡率和90天死亡率分别为21%、29%和39%。与幸存者相比,非幸存者发生肺炎、入院后24小时内出现休克、接受IMV、使用血管活性药物和肾脏替代治疗的情况更多,同时APACHE II评分更高,入院时白蛋白水平和PaO2/FiO2比值更低,ICU住院时间和住院时间更长。逻辑回归分析确定APACHE II评分(比值比[OR],1.157;95%置信区间[CI],1.017 - 1.317;P = 0.026)、入院时PaO2/FiO2比值(OR,0.989;95% CI,0.978 - 0.999;P = 0.046)和血管活性药物使用(OR,8.827;95% CI,1.650 - 47.215;P = 0.011)是ICU死亡率的预测因素。APACHE II评分(OR,1.099;95% CI,1.021 - 1.182;P = 0.011)和入院时白蛋白水平(OR,0.169;95% CI,0.056 - 0.514;P = 0.002)是90天死亡率的预测因素。
APACHE II评分、PaO2/FiO2比值、血管活性药物使用和白蛋白水平是重症COPD合并急性高碳酸血症呼吸衰竭患者短期死亡率的重要预测因素。